For MZ SR:

Director-General Department of Pharmacy and Drug Policy MUDr. Adam Hlôška
Director of the Department of Classification, Pricing and Drug Policy PharmDr. Rastislav Pullmann
Officer of the Department of Classification, Pricing and Drug Policy of MVDr. Erika Hanzelyová

Chief Algeziology Expert:

MUDr. Ľubomíra Nemčíková

Principal specialist in palliative medicine:

Dr Kristina Križanová

Main experts submitted a request for amendment of Decree 435/2011 Z.z. , Decree of the Ministry of Health of the Slovak Republic on the method of determining the standard dose of the drug and the maximum amount of reimbursement of the health insurance company for the standard dose of the drug, from 28.11.2011. Z.z., paragraph 2 (a) b) propose an amendment to the original text: the same route of administration and the different pharmaceutical form or...
to: the same route of administration and different form of medication with the same...

The meeting was opened by the Director General of the Department of Pharmacy and Drug Policy MUDr. Adam Hlôška.

Dr. Križanova, MUDr.
They realise that a change to the Decree is the most difficult way to change, so they are now proposing an amendment to the Annex.
First of all, they are concerned with patients who cannot afford an extra charge for Sevredol € 13.8. This is particularly true for children who do not have comparable compensation. All other medicines of the same ATC group have SR forms that are not suitable for all indications and especially not for children. They claim that the pharmacokinetics of SR form and IR form are not comparable and therefore require that Sevredol be separated from other SR forms in the credit transfer group.

MZ SR:
MZ SR needs documentation to be able to divide the credit transfer group.
MZ SR sees possible way in the amendment of Decree No 435/2011 Z.z., its annexes. This is a more fundamental change on which the Minister for Health must comment. The amendment of the Decree must go through a standard legislative process.

The meeting was concluded by the Director General of the Department of Pharmacy and Drug Policy MUDr. Adam Dormouse

Approval: MUDr. Adam Hlôška
Verified by Dr Lubomir German
Dr Kristina Križanová

Signed by: MVDr. Erika Hanzely